Company intelligence / Profile preview

Progenesis

La Jolla, California, USA

Ownership: Private
Employees: ~28
Development stage: Other

Overview

Progenesis offers highly accurate embryo and carrier screening through NGS technology, supporting IVF cycles globally. Their offerings are considered among the most sensitive for 24-chromosome aneuploidy screening and single-gene disorders. Widely adopted by IVF centers, their tests have demonstrated consistent reliability and rapid turnaround, improving genetic diagnosis for preimplantation embryos and reducing risk of inheritable conditions for prospective parents

Therapeutic areas: Women's HealthRare Diseases
Modalities: Genetic testing
Industry: Molecular Diagnostics

Partnerships

IVF centersfertility clinicsacademic collaborations not individually named

Beyond the preview

Go deeper on Progenesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Progenesis.

Explore the full profile